Sarah Lindbo

462 citations

20 papers · 357 indexed · h-index 12

Co-authors: Sophia Hober Javad Garousi Vladimir Tolmachev Anna Orlova Jos Buijs Bogdan Mitran Johan Nilvebrant Hadis Honarvar
Topics: Monoclonal and Polyclonal Antibodies Research (17 papers)Radiopharmaceutical Chemistry and Applications (11 papers)Peptidase Inhibition and Analysis (6 papers)
Cited by: Radiology, Nuclear Medicine and Imaging Oncology Biotechnology
Journals: Cancer Research Scientific Reports International Journal of Molecular Sciences
Partner nations: Sweden Russia United States

In The Last Decade

Sarah Lindbo

17 papers receiving 351 citations

Peers

Countries citing papers authored by Sarah Lindbo

Since Specialization

Citations

This map shows the geographic impact of Sarah Lindbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Lindbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Lindbo more than expected).

Fields of papers citing papers by Sarah Lindbo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Lindbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Lindbo. The network helps show where Sarah Lindbo may publish in the future.

Co-authorship network of co-authors of Sarah Lindbo

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Lindbo. A scholar is included among the top collaborators of Sarah Lindbo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Lindbo. Sarah Lindbo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reduction of renal activity retention of radiolabeled albumin binding domain‑derived affinity proteins using a non‑residualizing label strategy compared with a cleavable glycine‑leucine‑glycine‑lysine‑linker 2023 ·Molecular Medicine Reports ·(unknown),Anzhelika Vorobyeva,(unknown),Sarah Lindbo,Tianqi Xu,Maryam Oroujeni,Sara S. Rinne,Ulrika Rosenström,Javad Garousi	0
2	An easy-to-use high-throughput selection system for the discovery of recombinant protein binders from alternative scaffold libraries 2023 ·Protein Engineering Design and Selection ·(unknown),(unknown),Magnus Lundqvist,(unknown),(unknown),Emma Larsson,Johan Rockberg,Mathias Uhlén,Sarah Lindbo,Hanna Tegel,Sophia Hober	1
3	Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy 2022 ·International Journal of Molecular Sciences ·Vladimir Tolmachev,(unknown),Maryam Oroujeni,Sergey M. Deyev,Е. В. Коновалова,Alexey Schulga,Sarah Lindbo,Sophia Hober,Olga Bragina,Anna Orlova,Anzhelika Vorobyeva	5
4	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution 2020 ·Pharmaceutics ·(unknown),(unknown),(unknown),Sarah Lindbo,Hao Liu,Javad Garousi,Tianqi Xu,Anna Orlova,Vladimir Tolmachev,Sophia Hober,Torbjörn Gräslund	7
5	Phase I Study of ^99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer 2020 ·Journal of Nuclear Medicine ·Olga Bragina,(unknown),Javad Garousi,Roman Zelchan,Mattias Sandström,Anna Orlova,(unknown),(unknown),Anzhelika Vorobyeva,Sarah Lindbo,(unknown),(unknown),Jens Sørensen,Sophia Hober,В. И. Чернов,Vladimir Tolmachev	40
6	Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein 2020 ·Molecules ·Anzhelika Vorobyeva,Maryam Oroujeni,Sarah Lindbo,Sophia Hober,Tianqi Xu,(unknown),Sara S. Rinne,Javad Garousi	9
7	Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension 2020 ·Molecular Pharmaceutics ·(unknown),Sarah Lindbo,Magnus Lundqvist,(unknown),(unknown),Sara Kanje,Johan Rockberg,Hanna Tegel,(unknown),Mathias Uhlén,Sophia Hober	6
8	Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6 2019 ·European Journal of Pharmaceutics and Biopharmaceutics ·(unknown),Javad Garousi,Sarah Lindbo,Anzhelika Vorobyeva,Mohamed Altai,Maryam Oroujeni,Bogdan Mitran,Anna Orlova,Sophia Hober,Vladimir Tolmachev	21
9	Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin�A 2019 ·International Journal of Oncology ·Hao Liu,Sarah Lindbo,(unknown),Mohamed Altai,Javad Garousi,Anna Orlova,Vladimir Tolmachev,Sophia Hober,(unknown)	13
10	Quantum Dot–Based FRET Immunoassay for HER2 Using Ultrasmall Affinity Proteins 2018 ·Small ·(unknown),Xue Qiu,Sarah Lindbo,Kimihiro Susumu,Igor L. Medintz,Sophia Hober,Niko Hildebrandt	34
11	Bispecific applications of non-immunoglobulin scaffold binders 2018 ·Methods ·Sophia Hober,Sarah Lindbo,Johan Nilvebrant	20
12	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with ¹¹¹In and ⁶⁸Ga 2018 ·Molecular Pharmaceutics ·Sarah Lindbo,Javad Garousi,Bogdan Mitran,Anzhelika Vorobyeva,Maryam Oroujeni,Anna Orlova,Sophia Hober,Vladimir Tolmachev	15
13	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours 2018 ·European Journal of Pharmaceutics and Biopharmaceutics ·Javad Garousi,Sarah Lindbo,(unknown),(unknown),Anzhelika Vorobyeva,Maryam Oroujeni,Bogdan Mitran,Anna Orlova,Jos Buijs,Vladimir Tolmachev,Sophia Hober	23
14	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label 2017 ·Journal of Nuclear Medicine ·Sarah Lindbo,Javad Garousi,Bogdan Mitran,Mohamed Altai,Jos Buijs,Anna Orlova,Sophia Hober,Vladimir Tolmachev	33
15	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m 2017 ·Scientific Reports ·Javad Garousi,Sarah Lindbo,Bogdan Mitran,Jos Buijs,Anzhelika Vorobyeva,Anna Orlova,Vladimir Tolmachev,Sophia Hober	18
16	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6 2016 ·Bioconjugate Chemistry ·Javad Garousi,Sarah Lindbo,Hadis Honarvar,(unknown),Bogdan Mitran,Mohamed Altai,Anna Orlova,Vladimir Tolmachev,Sophia Hober	15
17	Investigating affinity-maturation strategies and reproducibility of fluorescence-activated cell sorting using a recombinant ADAPT library displayed on staphylococci 2016 ·Protein Engineering Design and Selection ·(unknown),Johan Nilvebrant,Mattias Björnmalm,Sarah Lindbo,Sophia Hober,John Löfblom	7
18	Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins 2016 ·Bioconjugate Chemistry ·Sarah Lindbo,Javad Garousi,(unknown),Hadis Honarvar,Anna Orlova,Sophia Hober,Vladimir Tolmachev	37
19	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers 2015 ·Cancer Research ·Javad Garousi,Sarah Lindbo,Johan Nilvebrant,(unknown),Jos Buijs,Mattias Sandström,Hadis Honarvar,Anna Orlova,Vladimir Tolmachev,Sophia Hober	53
20	Development of ADAPT6 as a new scaffold protein for radionuclide molecular imaging 2014 ·European Journal of Nuclear Medicine and Molecular Imaging ·Javad Garousi,Sarah Lindbo,Anna Orlova,(unknown),Johan Nilvebrant,Jos Buijs,Mattias Sandström,Hadis Honarvar,Vladimir Tolmachev,Sophia Hober	0

About Sarah Lindbo

Sarah Lindbo is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology, having authored 20 papers that have together received 357 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (17 papers), Radiopharmaceutical Chemistry and Applications (11 papers) and Peptidase Inhibition and Analysis (6 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (294 citations), Oncology (203 citations) and Biotechnology (14 citations). Sarah Lindbo has collaborated with scholars based in Sweden, Russia and United States. Frequent co-authors include Sophia Hober, Javad Garousi, Vladimir Tolmachev, Anna Orlova, Jos Buijs, Bogdan Mitran, Johan Nilvebrant, Hadis Honarvar, Anzhelika Vorobyeva and Mohamed Altai. Their work appears in journals such as Cancer Research, Scientific Reports and International Journal of Molecular Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact